PE-0121

N/A

Report date: 2025/01/26 17:44:31

Base Information

Drug NamePE-0121
Drug Alias NameNKG2A antagonist (Shanghai ChemPartner/Hyamab Pharmaceutical)NKG2A checkpoint inhibitor (Shanghai ChemPartner/Hyamab Pharmaceutical)anti-NKG2A mAb (Shanghai ChemPartner/Hyamab Pharmaceutical)PE-0121
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionNK cell lectin-like receptor subfamily C member 1 antagonists
TargetsNK cell lectin-like receptor subfamily C member 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Chem Partner Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Chem Partner Co LtdJiangsu Huaiyu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A